DEXAMETHASONE

Leukemia, Myeloid

University of FloridaSmall moleculePhase 2Dormant

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 48/ 100
Competitive Position: 81/ 100

Competitive context

16 Active assets in the Leukemia, Myeloid cohort.

Asset / Sponsor	Phase	Rating
Cytosin-Arabinosid M.D. Anderson Cancer Center	Phase 3	BB
ETOPOSIDE Instituto de Investigación Hospital Universitario La Paz	Phase 2	B
Enasidenib Tian Yi Zhang	Phase 3	B
Azacitidine Jacqueline Garcia, MD	Phase 3	B
Anti-Thymoglobulin, Rabbit Dartmouth-Hitchcock Medical Center	Phase 3	B

View all 37 →

Same molecule, other indications

DEXAMETHASONE is also rated in:

chemotherapy-induced toxicityDormant

A

Indicative ·

82 / 100

adult acute lymphoblastic leukemiaDormant

BBB

Indicative ·

79 / 100

B-cell childhood acute lymphoblastic leukemiaDormant

BBB

Indicative ·

78 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.